Class I antiarrhythmic drugs: Quinidine, procainamide, disopyramide, lidocaine, mexiletine, flecainide, and propafenone

Cardiac Electrophysiology: From Cell to Bedside

Volumn , Issue , 2004, Pages 911-917

  Gillis, Anne M ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85076646628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50102-0     Document Type: Chapter

References (40)

1. MS Stanton Class I antiarrhythmic drugs: Quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, phenytoin, moricizine, flecainide, propafenone DP Zipes., J Jalife Cardiac Electrophysiology: From Cell to Bedside 3rd ed. 2000 WB Saunders Philadelphia 890-903.
2. DM Roden Antiarrhythmic drugs JG Hardman., LE Limberg Goodman and Gilmans’s The Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill New York 933-970.
3. DM Roden Mechanisms and management of proarrhythmia Am J Cardiol 82 1998 49I-57I.
4. Gillis AM. Proarrhythmia syndromes. In Electrophysiological Disorders of the Heart. Philadelphia, WB Saunders, in press.
5. RH Falk Atrial fibrillation N Engl J Med 344 2001 1067-1078.
6. AA Grace., AJ Camm Quinidine N Engl J Med 338 1998 35-45.
7. AO Grant Propafenone: An effective agent for the management of supraventricular arrhythmias J Cardiovasc Electrophysiol 7 1996 353-364.
8. V Fuster., LE Ryden., RW Asinger., et al. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology Circulation 104 2001 2118-2150.
9. AA Paul., HJ Witchel., JC Hancox Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine Br J Pharmacol 136 2002 717-729.
10. Z Wang., B Fermini., S Nattel Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes J Pharmacol Exp Ther 272 1995 184-196.
11. + channel J Cardiovasc Pharmacol 32 1998 521-526.
12. L Virag., A Varro., JG Papp Effect of disopyramide on potassium currents in rabbit ventricular myocytes Naunyn Schmiedebergs Arch Pharmacol 357 1998 268-275.
13. K and its response to quinidine in experimental healed myocardial infarction J Cardiovasc Electrophysiol 10 1999 844-854.
14. AM Gillis., LB Mitchell., DG Wyse., et al. Quinidine pharmacodynamics in patients with arrhythmia: Effects of left ventricular function J Am Coll Cardiol 25 1995 989-994.
15. AM Gillis., TA Geonzon., HJ Mathison., et al. The effects of barium, dofetilide and 4-aminopyridine on ventricular repolarization in normal and hypertrophied rabbit heart J Pharmacol Exp Ther 285 1998 262-270.
16. M Zabel., SH Hohnloser., S Behrens., et al. Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart J Cardiovasc Electrophysiol 8 1997 1239-1245.
17. RE Benton., M Sale., DA Flockhart., et al. Greater quinidine-induced QTc interval prolongation in women Clin Pharmacol Ther 67 2000 413-418.
18. KE Thummel., DD Shen Design and optimization of dosage regimens: Pharmacokinetic data JG Hardman., LE Limberg Goodman and Gilmans’s The Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill New York 1917-2023.
19. GR Wilkinson Pharmacokinetics JG Hardman., LE Limberg Goodman and Gilmans’s The Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill New York 3-29.
20. B Thibault., S Nattel Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: Protagonist J Cardiovasc Electrophysiol 10 1999 472-481.
21. JW Mason., FI Marcus., JT Bigger., et al. A summary and assessment of the findings and conclusions of the ESVEM trial Prog Cardiovasc Dis 38 1996 347-358.
22. GV Naccarelli., P Dorian., SH Hohnloser., et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group Am J Cardiol 77 1996 53A-59A.
23. The AFFIRM First Antiarrhythmic Drug Substudy Investigators Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug administered J Am Coll Cardiol 42 2003 20-29.
24. D Roy., M Talajic., P Dorian., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators N Engl J Med 342 2000 913-920.
25. SH Hohnloser., A van de Loo., F Baedeker Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine J Am Coll Cardiol 26 1995 852-858.
26. P Varriale., A Sedighi., M Mirzaietehrane Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome Pacing Clin Electrophysiol 22 1999 1267-1269.
27. AP Gorgels., A van den Dool., A Hofs., et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia Am J Cardiol 78 1996 43-46.
28. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Advanced cardiovascular life support: 7B: Understanding the algorithm approach to ACLS. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation Circulation 102 2000 I140-I141.
29. R Brugada., J Brugada., C Antzelevitch., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts Circulation 101 2000 510-515.
30. AM Gillis., DG Wyse Supraventricular tachycardia JD Gray. Therapeutic choices 3rd ed. 2000 Canadian Pharmacists Association Ottawa, Ontario, Canada 241-252.
31. A Pinter., P Dorian Intravenous antiarrhythmic agents Curr Opin Cardiol 16 2001 17-22.
32. L Labbe., J Turgeon Clinical pharmacokinetics of mexiletine Clin Pharmacokinet 37 1999 361-384.
33. ZP Sadowski., JH Alexander., B Skrabucha., et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction Am Heart J 137 1999 792-798.
34. + channel blockade and to increases in heart rate. Implications for gene-specific therapy Circulation 92 1995 3381-3386.
35. W Shimizu., C Antzelevitch Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes Circulation 98 1998 2314-2322.
36. A Seki., N Hagiwara., H Kasanuki Effects of propafenone on K currents in human atrial myocytes Br J Pharmacol 126 1999 1153-1162.
37. E Jazwinska-Tarnawska., K Orzechowska-Juzwenko., P Niewinski., et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment Int J Clin Pharmacol Ther 39 2001 288-292.
38. KH Kuck., R Cappato., J Siebels., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH) Circulation 102 2000 748-754.
39. DG Wyse., M Talajic., GE Hafley., et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): Drug testing and as-treated analysis J Am Coll Cardiol 38 2001 344-351.
40. SG Priori., C Napolitano., PJ Schwartz., et al. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge Circulation 102 2000 945-947.